BioSpace News Archive

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced that the company has enrolled the first patient in a study evaluating the safety and efficacy of the Technolas® TENEO™ excimer laser* for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for hyperopia with astigmatism.

IRMS is excited to announce that Dr. Sarah M. Moustafa has joined their practice. Dr. Moustafa is board certified in Obstetrics & Gynecology and board eligible in Reproductive Endocrinology & Infertility.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced positive interim results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia.

Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity.

Palatin Technologies, Inc. today announced preliminary fourth quarter 2022 Vyleesi® product sales.

Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will host a conference call and webcast on Thursday, July 28, 2022, at 8:30 a.m. ET to review the results from the pivotal clinical trial of BT-001 after 180 days of treatment for type 2 diabetes.

Organicell Regenerative Medicine, Inc . (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics in the extracellular vesicle space, announced today that the board of directors has appointed Matt Sinnreich as Chief Operating Officer and acting CEO.

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), today announces that it has received Issue Notification from the United States Patent and Trademark Office that its patent application no. 17/459,284 will be granted on August 9, 2022 in the United States under patent no. 11,406,619 for novel injectable formulations of N,N-dimethyltryptamine (“DMT”) based compounds.

RLDatix, the international leader in governance, risk and compliance (GRC) solutions for healthcare, announced today the acquisition of Galen Healthcare Solutions (Galen), the market leader in implementation, optimization, data migration and archival solutions for HIT systems.

Oramed Pharmaceuticals Inc. announced today that it has enrolled and randomized over 50% of the planned 450 patients for its international multicenter Phase 3 ORA-D-013-2 trial of its oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D).